Do generic utility measures capture what is important to the quality of life of people with multiple sclerosis? by unknown
Kuspinar and Mayo Health and Quality of Life Outcomes 2013, 11:71
http://www.hqlo.com/content/11/1/71RESEARCH Open AccessDo generic utility measures capture what is
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Purpose: The three most widely used utility measures are the Health Utilities Index Mark 2 and 3 (HUI2 and HUI3),
the EuroQol-5D (EQ-5D) and the Short-Form-6D (SF-6D). In line with guidelines for economic evaluation from
agencies such as the National Institute for Health and Clinical Excellence (NICE) and the Canadian Agency for Drugs
and Technologies in Health (CADTH), these measures are currently being used to evaluate the cost-effectiveness of
different interventions in MS. However, the challenge of using such measures in people with a specific health
condition, such as MS, is that they may not capture all of the domains that are impacted upon by the condition. If
important domains are missing from the generic measures, the value derived will be higher than the real impact
creating invalid comparisons across interventions and populations. Therefore, the objective of this study is to
estimate the extent to which generic utility measures capture important domains that are affected by MS.
Methods: The available study population consisted of men and women who had been registered after 1994 in
three participating MS clinics in Greater Montreal, Quebec, Canada. Subjects were first interviewed on an
individualized measure of quality of life (QOL) called the Patient Generated Index (PGI). The domains identified with
the PGI were then classified and grouped together using the World Health Organization’s International Classification
of Functioning, Disability and Health (ICF), and mapped onto the HUI2, HUI3, EQ-5D and SF-6D.
Results: A total of 185 persons with MS were interviewed on the PGI. The sample was relatively young (mean age
43) and predominantly female. Both men and women had mild disability with a median Expanded Disability Status
Scale (EDSS) score of 2. The top 10 domains that patients identified to be the most affected by their MS were, work
(62%), fatigue (48%), sports (39%), social life (28%), relationships (23%), walking/mobility (22%), cognition (21%),
balance (14%), housework (12%) and mood (11%). The SF-6D included the most number of domains (6 domains)
important to people with MS, followed by the EQ-5D (4 domains) and the HUI2 (4 domains) and then the HUI3
(3 domains). The mean and standard deviation (SD) for the PGI, EQ-5D and the SF-6D were 0.50 (SD 0.25), 0.69
(0.18) and 0.69 (0.13), respectively. The magnitude of difference between the PGI and the generic utility measures
was large and statistically significant.
Conclusion: Although the generic utility measures included certain items that were important to people with MS,
there were several that were missing. An important consequence of this mismatch was that values of QOL derived
from the PGI were importantly and significantly lower than those estimated using any of the generic utility
measures. This could have a substantial impact in evaluating the effect of interventions for people with MS.
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Multiple sclerosis (MS) is a chronic disease resulting
from inflammation and demyelination in the central ner-
vous system (CNS) [1] that is associated with a variety of
symptoms, such as fatigue, impaired mobility and cogni-
tive decline [2]. Several new therapies, behavioural [3-9],
medical [10-14], and surgical [15-19], have been devel-
oped in the field of MS. As there are both benefits and
harms from interventions, the importance of considering
the patient’s perspective in the evaluation of these new
therapies is increasingly being emphasized. Patient-
reported outcomes are used to evaluate the patient’s per-
spective on the impact of the disease and its treatment
on symptoms, function, and other aspects of quality of
life (QOL). QOL is defined as an “individuals’ perception
of their position in life in the context of the culture in
which they live and in relation to their goals, expecta-
tions, standards and concerns [20].” QOL is a global
construct that includes domains other than health such
as job satisfaction, quality of housing, and the neighbor-
hood in which one lives [21]. Health-related quality of
life (HRQL), on the other hand, is a construct that is
narrower and focuses on domains within the purview of
the health care system, such as normal ranges for
physiological variables, physical, mental and social well-
being [22,23]. Health status, a term often confused with
HRQL, is a description and/or measurement of the
health of an individual or population at a particular
point in time against identifiable standards [24].
While there are a common set of domains that are
relevant across a wide variety of health conditions,
including none, these domains may be affected differen-
tially because of the positive and negative effects of
interventions. For example, a treatment may have a posi-
tive effect on one domain (e.g. mental health) but a
negative one on another (e.g. physical health) and this
would be condition and intervention specific.
The most widely used methodology to create an index
that weighs gains in one domain against losses in an-
other is based on utility theory. Utility measures (or
preference-based measures) provide a single value for
the construct (health status, HRQL, or QOL) ranging
from 0 (for death or worst possible health state) to 1 (for
perfect health or best possible health state) [25-29]. This
value is used to calculate what is termed a “Quality-
Adjusted Life Year” (QALY) which captures the effect of
an intervention on quantity of life (mortality) and “qual-
ity of life” (which is conceptualized as morbidity)
[30-33]. The “Q” in QALY is a misnomer given it mea-
sures only the health aspects of QOL, the other aspects,
which have been elegantly identified by Flanagan, are
physical and material well-being, relations with other
people, social community and civic activities, personal
development and fulfillment, and recreation [34].The three most widely used utility measures, namely the
Health Utilities Index Mark 2 and 3 (HUI2 and HUI3), the
EuroQol-5D (EQ-5D) and the Short-Form-6D (SF-6D),
label the constructs underlying these measures as health
status and/or HRQL [35-39]. None list QOL as the con-
struct being measured. Yet, for economic evaluation, the
QALY is the parameter calculated and compared with cost.
In line with guidelines for economic evaluation from
agencies such as the National Institute for Health and
Clinical Excellence (NICE) and the Canadian Agency for
Drugs and Technologies in Health (CADTH), these
measures are currently being used to evaluate the cost-
effectiveness of different interventions in MS. However,
the challenge of using such measures in people with a
specific health condition, such as MS, is that they may
not capture all of the domains that are impacted upon
by the health condition. If important domains are miss-
ing from the generic measures, the value derived will be
higher than the real impact creating invalid comparisons
across interventions and populations.
Personalized measures have been proposed as a
method for identifying those aspects of a health condi-
tion that impact on QOL. While they may differ from
person to person and across health conditions, the value
derived from them represents QOL. The most com-
monly used individualized measures of QOL are the
Patient Generated Index (PGI) and the Schedule for the
Evaluation of Individual Quality of Life-Direct Weighting
(SEIQOL-DW). Both measures capture the individual’s
perspective on QOL, by permitting him/her to nominate
the areas of life that are most important and assign a
weight to each domain. Personalized measures of QOL
have been used in several clinical trials to evaluate the
effectiveness of different interventions on overall QOL
[40-44]. Furthermore, these measures have shown to be
particularly useful in clinical settings by improving patient-
physician communication and by helping prioritize treat-
ment options [45-47].
The global aim of the study is to contribute evidence
for the content validity of generic utility measures with
respect to capturing the relevant domains for people
with MS. The specific objective was to estimate the ex-
tent to which generic utility measures capture important
domains that are affected by MS.
Methods
Subjects
The data for this study comes from a study of the life-
impact of people diagnosed with MS during the era of
magnetic resonance imaging (MRI) and disease modify-
ing therapies (the New MS) [48]. The available study
population consisted of both men and women who had
been registered after 1994 at the three participating MS
clinics in Greater Montreal, Quebec, Canada. The study
Figure 1 Flowchart of the study procedure.
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criteria for the study were diagnosis of MS or Clinically
Isolated Syndrome (CIS) after 1994. From a pool of 5000
patients, a centre-stratified random sample of 550 patients
was drawn, of which 394 were contacted. From those who
were contacted, the first 192 persons who responded were
enrolled, 189 completed all questionnaires and 185 came
for an interview. Respondents and non-respondents were
compared and no clinically or statistically significant




The PGI is an individualized measure of HRQL that was
administered in three stages. In the first stage, patients
were asked to identify up to five of the most important
areas of their lives affected by MS. In the second stage,
patients were asked to rate how badly affected they were
in each of the selected areas on a scale of 0 to 10, where
0 was the worst they can imagine and 10 exactly as they
would like to be. A sixth box was provided to rate all
other health or non-health related areas. In the third
stage, they were given twelve spending “points” or
“tokens” to distribute among the areas identified. The
tokens that they allocated to each area represented the
relative importance of potential improvements in the
chosen area. The more tokens a patient spent for an
area, the more important that area was. The less tokens
a patient spent, the less important that area was. The
rating for each area was multiplied by the proportion of
“points” for that area, which were then summed together
to produce an index from 0 to 100 [49]. For ease of
comparison with the utility measures, PGI scores in this
study were presented on a scale from 0 to 1.
EQ-5D
The EQ-5D is a generic preference-based measure of
HRQL that consists of two parts [50,51]. The first part
includes 5 separate domains; mobility, capacity for self-
care, conduct of usual activities, pain/discomfort and
anxiety/depression. Each domain has 3 levels: no prob-
lems, some problems, extreme problems. The second
part consists of a Visual Analogue Scale (EQVAS) to
measure self-perceived health on a vertical scale from 0
to 100, where 0 is the worst imaginable health state, and
10 is the best imaginable health state. The EQ-5D de-
fines 243 health states, and has a range from −0.6 to 1.0.
SF-6D
The SF-6D is a generic preference-based measure de-
rived from the SF-36 Health Survey (or RAND-36)
[23,39]. The SF-6D has 6 domains: physical functioning,
role limitation, social functioning, pain, mental healthand vitality. Each domain has between 4 and 6 levels.
The index defines 18 000 health states, and has a range
from 0.3 to 1.0.
Procedure
Figure 1 presents a flowchart of the study procedure.
Subjects were first interviewed on an individualized
measure of QOL, the PGI [49]. The domains identified
with the PGI were then classified and grouped together
using the World Health Organization’s International
Classification of Functioning, Disability and Health (ICF)
[52] independently by four raters. This methodology
followed closely that conducted by Mayo et al [53],
which evaluated the extent to which HRQL measures
captured constructs beyond symptoms and function.
The ICF provided a coding framework and standardized
description of health related problems at the level of
body structure/function (e.g. fatigue, cognition), activity
(e.g. dressing, feeding, walking) and participation (e.g.
school, work). These levels are also known as impair-
ments, activity limitations and participation restrictions,
respectively. Any discrepancies between raters were
resolved by discussion.
Last, the domains were mapped onto the HUI2, HUI3,
EQ-5D and SF-6D which had been previously mapped
to the ICF [53]. The extent to which these utility mea-
sures captured domains important to patients with MS
was qualitatively appraised.
Data analysis
We had data on hand for the PGI, the EQ-5D and the
SF-6D (derived from the RAND-36). As all three
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generalized estimating equations (GEE) was used to ad-
just the variance for the clusters of outcome within per-
sons. The advantage of using GEE, as opposed to the
paired t-test, was that it allowed for simultaneous assess-
ment and correlation among all 3 measures. The regres-
sion coefficients produced in the model were estimates
of the difference between measures (with 95% CI)
adjusted for the correlation among data points. An effect
size (ES) was then calculated using the t-statistic, which
was equal to the adjusted regression coefficient divided
by its SE.
Results
A total of 185 persons with MS were interviewed on the
PGI. The sample was relatively young (mean age 43) and
predominantly female. Both men and women had mild
disability with a median Expanded Disability Status Scale
(EDSS) score of 2. The average number of years since
diagnosis was 6 years, and 59% of the sample was on
Disease Modifying Therapies. Demographic and clinical
characteristics are presented in Table 1.
Table 2 presents the top 10 domains that patients
identified to be the most affected by their MS. These
areas were, work (62%), fatigue (48%), sports (39%), so-
cial life (28%), relationships (23%), walking/mobility
(22%), cognition (21%), balance (14%), housework (12%)
and mood (11%). The mean impact score for each
domain (from 0 to 10) ranged from 3.9 to 5.0. In terms
of the mean number of points spent for each domain,
patients spent the most points (4.3) to improve their
relationships, followed by fatigue (3.8) and then walking
(mean 3.6).Table 1 Demographic and clinical characteristics of
sample (n = 185)
Characteristics Mean (SD) or N (%)
Age (y) 42.8 (10.0)
Women/Men 137/48 (74/26)
Definite MS/CIS 170/15 (92/8)
Year since diagnosis 6.2 (3.6)
EDSS, median (IQR) 2.0 (1.0 - 3.5)
On DMT/Not on DMT/No information 110/19/56 (59/10/30)
Patient Generated Index* 0.50 (0.25)
EQ-5D** 0.69 (0.18)
SF-6D*** 0.69 (0.13)
SD, standard deviation; N, number; CIS, Clinically Isolated Syndrome; EDSS,
Expanded Disability Status Scale; IQR, Inter-quartile range; DMT, Disease
Modifying Therapies.
*Transformed to a scale from 0 to 1, higher scores are better (1 = perfect QOL).
**Measured on a scale from −0.4 to 1, higher scores are better
(1 = perfect health).
***Measured on a scale from 0.3 to 1, higher scores are better
(1 = perfect health).Table 3 presents the results for the mapping of the 10
domains identified by MS patients against the HUI2,
HUI3, EQ-5D and the SF-6D. School/work was found in
the EQ-5D and SF-6D but not in the HUI2 or HUI3.
Fatigue was found in the SF-6D but not in the EQ-5D or
the HUI measures. Sports which was the third most fre-
quently reported domain, was only found in the SF-6D
and HUI2. Social life was included in the EQ-5D and the
SF-6D, but not in the HUI measures. Cognition was
found in the HUI measures, but not in the EQ-5D or
the SF-6D. Housework was included in the EQ-5D and
the SF-6D, but not in the HUI2 or HUI3. Relationships
and balance were not included in any of the utility mea-
sures. Mood was the only domain that was included in
all of the measures.
The SF-6D included the most number of domains
(6 domains) important to people with MS, followed
by the EQ-5D (4 domains) and the HUI2 (4 domains),
and then the HUI3 (3 domains).
The generic utility measures included domains that
were not identified to be important by the sample, such
as pain, self-care, vision, hearing, manual dexterity,
speech and fertility.
The correlation between the SF-6D and the EQ-5D
was 0.58. As demonstrated in Figure 2a, although the re-
lationship between the measures was somewhat linear,
discrepancies in scores between the two measures was
evident. At the upper end of the scales, a number of
individuals who had utility scores of 0.85 on the EQ-5D
had scores as low as 0.6 on the SF-6D. A clinically
meaningful difference on utility measures is 0.03, indi-
cating that the difference in scores between the two util-
ity measures was important. Discrepancies were also
observed at the lower end of the scale, where an individ-
ual with a score of 0.12 on the EQ-5D had a score of
0.55 on the SF-6D.
The correlation between the PGI and the EQ-5D was
0.53. As presented in Figure 2b there were important
discrepancies in scores between the two measures.
Several individuals with very low scores on the PGI (as
low as 0.1) had very high scores on the EQ-5D (as high
as 0.8). For many individuals, there was also a mismatch
between scores obtained using the PGI and those
obtained with the EQ-5D (i.e. individuals with scores as
low as 0.1 on the PGI had scores of 0.8 on the EQ-5D).
Pearson’s correlation between the PGI and the SF-6D
was 0.53. Similar to what was observed for the EQ-5D;
there were discrepancies in scores between the 2 mea-
sures, particularly towards the lower end of the scales
(Figure 2c).
The impact of a mismatch between domains provided
in the generic utility measures and those that are im-
portant to people with MS is illustrated by the total
scores of the measures. As seen in Figure 3, the mean










N (%) Mean (SD)* Mean (SD)**
School/Work 114 (62) 4.2 (3.4) 1.7 (2.0)
Fatigue 88 (48) 4.5 (2.2) 3.8 (2.7)
Sports 73 (39) 4.1 (2.6) 2.9 (2.4)
Social life 52 (28) 4.7 (2.4) 1.8 (2.6)
Relationships 43 (23) 4.8 (3.4) 4.3 (2.6)
Walking 41 (22) 3.9 (2.5) 3.6 (2.5)
Cognition 39 (21) 4.7 (2.1) 2.8 (2.2)
Balance 25 (14) 5.0 (2.3) 2.5 (3.3)
Housework 23 (12) 4.8 (2.1) 1.3 (1.0)
Mood 21 (11) 4.6 (2.4) 3.4 (2.6)
*Scored out of 10, higher is better (not affected).
**Scored out of 12, higher indicates that the domain was more important.
Table 3 The domains identified by MS subjects compared
with items in generic utility measures













School/Work N N Y Y
Fatigue N N N Y
Sports Y N N Y
Social life N N N Y
Relationships N N N N
Cognition Y Y N N
Walking Y Y Y N
Housework N N Y Y
Balance N N N N
Mood* Y Y Y Y
Total Yes
(out of 10)
4 3 4 6
Not MS
Domains
Pain Y Y Y Y
Self-care Y N Y Y
Vision Y Y N N
Hearing Y Y N N
Manual
dexterity
N Y N N
Speech Y Y N N
Fertility Y N N N
MS Domains ordered from the largest to the smallest proportion of people
with MS who identified that domain.
Y, Yes; N, No; HUI2, Health Utilities Index Mark 2; HUI3, Health Utilities Index
Mark 3; SF-6D, EQ-5D, EuroQol-5D; Short-Form 6D.
*In the HUI3 this was happiness.
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SF-6D were 0.50 (SD 0.25), 0.69 (SD 0.18) and 0.69 (SD
0.13), respectively. The magnitude of difference between
the PGI and the 2 utility measures was 0.19 (95% CI
0.16 to 0.22) with ES equal to 12.
This mismatch was also present at the item level. A
total of 41 subjects (22% of the sample) reported walking
to be an important aspect of their QOL. The distribution
of scores on the degree to which walking was affected
for these subjects is presented in Figure 4. The impact
was measured on a scale from 0 to 10 on the PGI, where
0 was the worst they could imagine and 10 was exactly
as they would like to be. These scores were compared
with the responses on the EQ-5D mobility item. 12 sub-
jects out of 41 reported having no problems with walk-
ing on the EQ-5D. These people were expected to have
a score of 10 on the PGI. Only 1 person reported a score
of 10 on the PGI. All other subjects reported scores
lower than this, scores as low as 3 (poor).Discussion
In this study, subjects with MS were interviewed on an
individualized measure to evaluate the impact of the dis-
ease on their QOL. The results of the interview gener-
ated a list of domains that were most important to the
QOL of persons with MS. The domains identified were
work, fatigue, sports, social life, relationships, walking,
cognition, balance, housework and mood. These were
then mapped onto generic utility measures to estimate
the extent to which they captured domains that were
important to persons with MS.
There was no one generic utility measure that cap-
tured all of the domains important to persons with MS.For example, fatigue, which affects 75 to 90% of patients
with MS [54-57] was not included in the EQ-5D or the
HUI measures. Walking, another commonly reported
symptom was not found in the SF-6D. Cognition was
not found in the EQ-5D or the SF-6D. Work, sports,
and social life were not found in the HUI2 or HUI3.
This was not surprising as the HUI measures were de-
veloped with the intention of evaluating ‘within-the-skin’
experiences that excluded social interaction [58-60]. Bal-
ance and relationships were not included in any of the
utility measures.
The generic utility measures were clearly missing do-
mains that were important to people with MS. Out of
the 10 domains that persons with MS identified as being
central to their QOL, only 3 of them were included in
the HUI2, 4 were included in the HUI3, 4 were included
in the EQ-5D and 6 were included in the SF-6D. Fur-
thermore, the generic utility measures included several
Figure 2 Relationship between the EQ-5D, the SF-6D and the Patient Generated Index. a: Scatter plot of the relationship between the
EQ-5D and the SF-6D. b: Scatter plot of the relationship between the Patient Generated Index and the EQ-5D. c: Scatter plot of the relationship
between the Patient Generated Index and the SF-6D.
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Figure 3 Mean and standard deviation values for the PGI,
EQ-5D and SF-6D, with differences and 95% CI calculated using
generalized estimating equations.
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sampled in the study, such as pain, self-care, hearing and
manual dexterity.
To tackle the issue of lack of content validity, one
emerging area of interest in the literature is the develop-
ment of disease specific “bolt-ons” or dimension exten-
sions to generic utility measures [51]. Another emerging
area of interest is the development of disease-specific
utility measures, which have been developed for stroke
[61], pulmonary hypertension [62], asthma [63], rhinitis
[64], urinary incontinence [65] and erectile dysfunction
[66]. Recently, Versteegh et al. [67] derived a MS specificFigure 4 Frequency and distribution of PGI scores on the degree to w
(exactly as they would like to be).utility measure from the Multiple Sclerosis Impact
Scale-29 (MSIS-29) using Rasch analysis. The authors
selected 8 out of 29 items from the original question-
naire. Some important dimensions such as social life,
work and mood were included while others such as
walking, sports and physical fatigue were omitted.
There are several potential benefits to using disease spe-
cific utility measures in clinical and cost-effectiveness re-
search. First, disease specific utility measures are designed
to include domains that are specific to a disease, and
therefore, are likely to be more sensitive to smaller change
over time than generic measures. Second, not only do
these measures provide descriptive information on the
various dimensions of health, but also provide a value for
each one, thus allowing trade-offs to be made between the
domains. Disease-specific utility measures serve the po-
tential to overcome one of the challenges associated with
disease specific health profiles - that domains cannot be
combined into a single index, which makes it difficult to
conclude whether an intervention was effective or not.
For example, if a treatment has a positive effect on phys-
ical health but a negative one on mental health, unless we
know the relative importance attached to each domain, it
is impossible to determine whether the intervention
resulted in a net improvement or decline in QOL/HRQL.
Furthermore, disease-specific utility measures can be used
to calculate QALYs and make decisions on the cost-
effectiveness of different treatments in MS.
A clinician reported outcome (ClinRO) is an assess-
ment of the status of a patient’s health condition that ishich walking was affected from 0 (worst they can imagine) to 10
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ician) [69]. ClinRO are commonly used for endpoints
that cannot be directly measured by the patient (e.g.
EDSS to quantify level of disability in MS). An observer-
reported outcome (ObsRO) is an assessment that is
made by an observer without professional training (i.e.
non-clinician observer such as a teacher or caregiver)
[69]. This type of evaluation is typically used when the
patient is unable to self-report. A patient reported out-
come (PRO) is any report of the status of a patient’s
health condition that comes directly from the patient,
without interpretation of the patient’s response by a clin-
ician or other observer (e.g. symptoms, QOL, HRQL)
[68,69]. PROs play a complementary role in outcome as-
sessment by providing evidence on the benefit or harm
of a treatment from the patient’s perspective. Utility
measures are one type of PRO. In outcome assessment,
utility measures not only provide information on the
benefits and harms of a treatment, but are also useful
for economic applications by producing QALYS. This in-
formation can provide policy and decision makers with a
means of evaluating the costs and cost-effectiveness of
different treatment options for a health condition.
The first step in evaluating the validity of scores
produced by a PRO is an assessment of content validity,
before any other forms of validity (i.e. construct validity)
are undertaken. Content validity of a PRO can be judged
only by the individuals or populations being assessed (i.
e. the patients themselves). The global aim of this study
was to address this very question of whether generic
utility measures captured domains that were important
or relevant to people with MS. The results of this study
suggest that many important domains in MS are not cap-
tured by generic utility measures, therefore questioning
the content validity of such measures in MS. This in turn,
adds doubt to the interpretability or meaningfulness of
scores produced by these measures for this population.
It is important to target measures to people to ensure
that the impact of a disease and its treatment are ad-
equately and reliably captured in a clinical trial [70,71].
If a PRO includes domains that are not impacted upon
by the disease or its treatment, it will not be able to cap-
ture clinically meaningful change. By targeting to the
disease, measures are more likely to be sensitive to small
but important clinical changes. Furthermore, the ability
of PROs to detect small changes is important in deter-
mining the statistical power or the necessary sample size
required for a clinical trial [72].
The results of our study revealed that the commonly
used 4 generic utility measures (HUI2, HUI3, EQ-5D
and SF-6D) do not capture the majority of domains im-
portant to MS. Among these generic measures, the SF-
6D captured the most number of domains (6 domains)
that were important to MS. Our findings suggest thatthe SF-6D, compared to the other generic utility mea-
sures, may be the most appropriate one to use in MS.
The PGI index can be used to evaluate the clinical ef-
fectiveness of different interventions in MS. However,
because the PGI was not developed using multi-attribute
utility theory (hence is not a utility measure); it cannot
be used for cost-utility analysis.
Ideas for future directions that build directly from this
work are the use of MS specific “bolt-on” items or di-
mensions to generic utility measures [73]. This study has
identified potential items important to MS, such as fa-
tigue that can be used as add-ons to existing generic
utility measures. Other areas of potential research that
can build directly from this work are the development of
an MS specific utility measure that will only include di-
mensions pertinent to the disease.
A particular feature of this study is that we purposely
sampled people with MS diagnosed in the era of
Magnetic Resonance Imaging (MRI) technology and
availability of disease modifying drugs [48]. As these are
the people who are faced with treatment decisions, a
method of valuing changes on the most important do-
mains of QOL affected by MS would be the most rele-
vant for this population.
Conclusions
Generic utility measures are designed to include a com-
mon set of dimensions that most people will value
highly, therefore underrepresenting those dimensions
that may be specific to a particular disease. Although the
generic utility measures included certain items that were
important to people with MS, there were several that
were missing. An important consequence of this mis-
match was that values of QOL derived from the PGI
were importantly and significantly lower than those esti-
mated using any of the generic utility measures. This
could have a substantial impact for evaluating the effect
of interventions in people with MS. The overestimation
in scores obtained with utility measures may not have an
impact at the start of a clinical trial, but they will have
an impact at follow-up. If scores are high at baseline,
there will likely be no room for improvement on the
scale, resulting in the false conclusion that the treatment
group did not change post-treatment. When in reality,
the treatment may have had a positive effect but the
measure being administered was not able to detect this.
Then the difference between the treatment and control
group (assuming the control also does not change),
would be zero. In addition, an intervention that is in fact
beneficial to fatigue, for example, would also risk not to
show change on a generic measure because this item
was not included. When choosing the right outcome
measure for an intervention, it is essential to choose one
with items that can or should be affected by the
Kuspinar and Mayo Health and Quality of Life Outcomes 2013, 11:71 Page 9 of 10
http://www.hqlo.com/content/11/1/71intervention. Given that the MS specific items do impact
on QOL, not including these items would result in a
false estimate of QALYs and bias the evaluation of the
cost-effectiveness of interventions in MS.
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